Where is the withdrawal recorded?
The FDA notice names both old Geref drug approvals and says they ended in June 2009.
Read the withdrawal noticeA guide for the questions behind a search for sermorelin care.
Was it taken away because it was dangerous?
The word “withdrawn” can sound alarming. It helps to ask what was withdrawn, and what the official finding actually said.
The mix-up
Does leaving the market mean a drug failed on safety?
In sermorelin’s case
FDA, the US agency that reviews medicines, made a finding about sermorelin (Geref) in March 2013.
Safety concerns or a failure to work were not the reasons Geref left the market, FDA found.
That historical finding is not an endorsement of a product offered today.
What did the maker do?
In 2008, Geref’s maker stopped selling it and asked FDA to end its approvals.
The approvals ended on June 18, 2009.
The FDA notices do not give the maker’s business reason.
Did the later finding bring it back?
No. The finding opened a possible route for a generic copy, meaning an approved copy of the old drug.
As of September 28, 2026, no generic sermorelin product had gained approval.
What question matters for my visit?
Ask what product would actually be supplied. Then ask who makes it. An answer about the old product’s history leaves that question open.
What backs this answer?
Follow the record, at your pace.
Where is the later finding?
FDA published the safety-and-effectiveness finding in March 2013.
Read the later FDA finding